Research Reports | Market Assessment
April 2015

Malignant Melanoma (First-Line Unresectable/Metastatic) | Decision Base | US | 2015

Will the Emerging Immunotherapies and BRAF/MEK Inhibitor Combinations Meet Physicians’ and Payers’ Expectations?

In recent years, several new, high-priced therapies have been approved for use in first-line unresectable/metastatic malignant melanoma, making this relatively small market more dynamic and competitive. The launch of these agents has significantly altered the treatment algorithm and improved the outlook for patients; nevertheless, our research indicates that significant clinical and commercial opportunity remains for therapies that can further prolong overall survival (OS). Several therapies are in late-stage development for first-line unresectable/metastatic malignant melanoma, all of which are showing considerable potential for improving efficacy outcomes in this indication.

Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports